Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

Bibliographic Details
Main Authors:	Michael Ament, Kathleen Day, Virginia L. Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora
Format:	Article
Language:	English
Published:	BMC 2021-08-01
Series:	The Journal of Headache and Pain
Online Access:	https://doi.org/10.1186/s10194-021-01307-6

Similar Items

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
by: Michael Ament, et al.
Published: (2021-02-01)

Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials
by: Jakub Jedynak, et al.
Published: (2021-05-01)

Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial
by: Fumihiko Sakai, et al.
Published: (2020-07-01)

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
by: Stephen D. Silberstein, et al.
Published: (2019-12-01)

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
by: Stephen D. Silberstein, et al.
Published: (2019-06-01)

Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
by: Mark E. Bangs, et al.
Published: (2020-03-01)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
by: Mark E. Bangs, et al.
Published: (2020-01-01)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-10-01)

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
by: Jessica Ailani, et al.
Published: (2020-10-01)

Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
by: Stefanie Förderreuther, et al.
Published: (2018-12-01)

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
by: Dulanji K. Kuruppu, et al.
Published: (2021-04-01)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
by: Panagiotis Gklinos, et al.
Published: (2021-03-01)

Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine
by: Virginia L. Stauffer, et al.
Published: (2020-05-01)

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
by: Angelo Camporeale, et al.
Published: (2018-11-01)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
by: Bianca Raffaelli, et al.
Published: (2019-06-01)

CORRELATION BETWEEN MIGRAINE SEVERITY AND COMORBIDITIES IN EPISODIC MIGRAINE PATIENTS
by: Adriana Bulboaca, et al.
Published: (2015-06-01)

Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study
by: Shibata M, et al.
Published: (2020-12-01)

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
by: Virginia L. Stauffer, et al.
Published: (2020-06-01)

Efficacy of galcanezumab in patients with episodic cluster headaches and a history of preventive treatment failure
by: Brian Plato, et al.
Published: (2021-05-01)

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
by: Panagiotis Gklinos, et al.
Published: (2020-04-01)

Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients
by: Ammendola, E., et al.
Published: (2022)

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
by: Fabrizio Vernieri, et al.
Published: (2021-05-01)

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
by: Ford JH, et al.
Published: (2018-11-01)

Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy
by: Lupi C, et al.
Published: (2019-04-01)

Episodic Mydriasis as Migraine Equivalent
by: J Gordon Millichap
Published: (1991-10-01)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab
by: Pellesi L, et al.
Published: (2020-07-01)

CURRENT THERAPIES IN EPISODIC MIGRAINE MANAGEMENT
by: Adina Roceanu,, et al.
Published: (2014-12-01)

Migraine Episodes Following Cranial Irradiation
by: J Gordon Millichap
Published: (1995-11-01)

The acute and preventative treatment of episodic migraine
by: Sarah Miller
Published: (2012-01-01)

Migraine with benign episodic unilateral mydriasis
by: Jabr FI, et al.
Published: (2011-06-01)

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
by: Yanbo Yang, et al.
Published: (2020-02-01)

Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study
by: Rose Okonkwo, et al.
Published: (2021-09-01)

The genetic characterisation of classical migraine and episodic ataxia
by: Cader, M. Zameel
Published: (2004)

Cranial Autonomic Symptoms in Migraine
by: J Gordon Millichap
Published: (2009-11-01)

Migraine Diagnoses and Symptom Patterns
by: J Gordon Millichap
Published: (1993-11-01)

Migraine Associated Symptom Prevalence
by: J Gordon Millichap
Published: (1995-08-01)

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
by: Russell Nichols, et al.
Published: (2019-03-01)

Purinergic Profiling of Regulatory T-cells in Patients With Episodic Migraine
by: Dilyara Nurkhametova, et al.
Published: (2018-09-01)

Pediatric Episodic Migraine with Aura: A Unique Entity?
by: Hannah F.J. Shapiro, et al.
Published: (2021-03-01)

The Psychometric Properties of the Persian Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraines
by: Alireza Zandifar, et al.
Published: (2013-01-01)